Tangram to Present Clotting Drug Data in December
The liver-targeted siRNA TGM-148 is preclinical and could reach human trials in 2027, with a target of four or fewer doses a year.
Updated on Nov. 4, 2026 in Biotech
Tangram Therapeutics will present preclinical data for TGM-148, a liver-targeted small interfering RNA (siRNA) that silences a natural clotting regulator, at the ASH 68th Annual Meeting on December 14, 2026. The compound is at the preclinical stage in animal studies, and a Phase 1 trial in healthy volunteers is underway.
Why it matters
TGM-148 targets Protein Z-dependent Protease Inhibitor (ZPI), a natural brake on blood coagulation, which places it in the effort to build prophylactic therapies for bleeding disorders delivered by infrequent injection. Its data will be judged against the broader field of RNA-based treatments for hemophilia-type conditions, where dosing convenience and safety margins are the central competitive questions.
The preclinical evidence comes from animal disease models and a repeat-dose toxicology study in healthy non-human primates, in which TGM-148 was well tolerated up to the highest dose tested. The company's stated target is four or fewer subcutaneous doses a year, but human pharmacokinetic and safety figures have not yet been published.
The players
Tangram Therapeutics
A London-based biotechnology company developing RNA-based therapeutics, including the GalNAc-conjugated siRNA TGM-148, with its lead program in clotting regulation.
American Society of Hematology (ASH)
The professional society that hosts the ASH Annual Meeting, one of the largest venues for hematology and blood-disorder research data.
The details
TGM-148 is a GalNAc-conjugated small interfering RNA, meaning a short strand of genetic material that triggers the cell's own machinery to destroy a specific messenger RNA, attached to a sugar-based tag that binds a receptor on liver cells. The design selectively silences ZPI in the liver, where the protein is produced. ZPI normally limits clotting, so reducing it is intended to boost thrombin generation, the process that forms the clot's core, in patients who lack certain clotting factors. The compound is given by subcutaneous injection, meaning under the skin.
Timeline
December 12-15, 2026: ASH 68th Annual Meeting in New Orleans, Louisiana.
December 14, 2026, 14:45-16:15: Oral presentation session on TGM-148 data.
2027: Initial Phase 1 trial data anticipated.
The Tech Race
Tangram's ZPI-silencing approach competes with other RNA and protein-based strategies aimed at prophylaxis for clotting disorders, where dosing frequency is a key point of differentiation. The field's trajectory will be shaped by whether human Phase 1 data confirm the non-human primate thrombin-generation effect without compromising the safety margin shown in toxicology.
No patient-facing availability, pricing or approval timeline has been announced, and the compound remains in clinical testing. Any eventual use would depend on Phase 1 safety data in healthy volunteers and later trials in patients with clotting disorders.
The takeaway
The key trajectory is whether TGM-148's thrombin-generation effect, shown only in factor VIII-depleted primate plasma, translates into human safety and dosing convenience. Watch the December 14, 2026 ASH oral session and the initial Phase 1 data expected in 2027 for the first human evidence.
What happens next
Oral presentation of TGM-148 preclinical data at the ASH Annual Meeting on December 14, 2026, followed by initial Phase 1 trial data anticipated in 2027.
Further reading
For background on how these therapies are engineered, explore more Biotech coverage.
More information
Details on the company's pipeline are available on the Tangram Therapeutics company website.
